Summit Investment Advisors Inc. Boosts Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Summit Investment Advisors Inc. increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 3.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,595 shares of the company’s stock after purchasing an additional 82 shares during the quarter. Summit Investment Advisors Inc.’s holdings in Krystal Biotech were worth $407,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in KRYS. US Bancorp DE boosted its stake in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after purchasing an additional 82 shares during the period. Crossmark Global Holdings Inc. boosted its position in shares of Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after acquiring an additional 121 shares during the period. Envestnet Asset Management Inc. grew its stake in Krystal Biotech by 1.1% during the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock valued at $1,822,000 after acquiring an additional 121 shares in the last quarter. Perigon Wealth Management LLC increased its holdings in Krystal Biotech by 1.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock worth $1,200,000 after acquiring an additional 123 shares during the period. Finally, Xponance Inc. lifted its stake in Krystal Biotech by 9.5% in the 4th quarter. Xponance Inc. now owns 1,785 shares of the company’s stock worth $280,000 after purchasing an additional 155 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target on the stock. Chardan Capital raised their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup raised their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech presently has an average rating of “Buy” and an average price target of $220.00.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company’s stock.

Krystal Biotech Stock Performance

Shares of KRYS opened at $168.57 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34. The firm has a 50 day moving average price of $175.10 and a 200-day moving average price of $171.86. The firm has a market cap of $4.87 billion, a price-to-earnings ratio of 56.38 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same period last year, the firm earned $0.30 earnings per share. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).